Caribou Biosciences, Inc. (CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, on Monday announced positive results from its ANTLER phase 1 study evaluating vispacabtagene regedleucel (vispa-cel), an allogeneic anti-CD19 CAR-T cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lymphoma. The announcement sent the company's shares more than 50% higher in pre-market trading.
Data from the confirmatory cohort, in which patients received vispa-cel at the recommended Phase 2 dose, showed that a single dose of partially matched vispa-cel achieved efficacy comparable to approved autologous CAR-T cell therapies, with an 82% overall response rate, 64% complete response rate, and 51% progression-free survival at 12 months. The median follow-up was six months, and vispa-cel was generally well-tolerated, enabling administration in the outpatient setting.
"This combination of robust clinical activity and accessibility could significantly broaden patient access to transformative CAR-T cell treatments, particularly for those who cannot wait or are ineligible for transplantation or autologous CAR-T cell therapies," , said Mehdi Hamadani, professor of medicine and section chief of hematologic malignancies at the Medical College of Wisconsin and an investigator on the ANTLER trial.
Caribou Biosciences' stock closed at $2.42, up 4.31% on Friday. The shares have traded between $0.66 and $3.00 over the past year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.